๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

New variant in exon 3 of the proteolipid protein (PLP) gene in a family with pelizaeus-merzbacher disease

โœ Scribed by Pratt, Victoria M. ;Trofatter, James A. ;Larsen, Marianne B. ;Hodes, M. E. ;Dlouhy, Stephen R.


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
357 KB
Volume
43
Category
Article
ISSN
0148-7299

No coin nor oath required. For personal study only.

โœฆ Synopsis


A C --> G transversion has been found in exon 3 of the PLP gene of affected males and their mother in a single sibship with Pelizaeus-Merzbacher disease (PMD). The transversion should not result in an amino acid change in the protein but it does result in the loss of a HaeIII restriction endonuclease cleavage site. It is concordant with the disease in this family. One-hundred-ten unrelated X chromosomes are negative for this mutation. No other sequence defect was found in the PLP exons of the affected males. The cause of disease in this family remains unknown, but the association between this rare mutation and PMD is intriguing. The mutation can serve as a marker for following segregation of the PLP gene.


๐Ÿ“œ SIMILAR VOLUMES


Nonsense mutation in exon 3 of the prote
โœ Hodes, M. E.; Blank, C. A.; Pratt, V. M.; Morales, J.; Napier, J.; Dlouhy, S. R. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 180 KB ๐Ÿ‘ 1 views

We report a Gโ†’A transition at nucleotide 431 of the proteolipid protein gene (PLP) results in a nonsense codon in a family with an unusual form of Pelizaeus-Merzbacher disease (PMD). The mutation, which creates a second AluI restriction site, results in a nonsense mutation in PLP. The clinical pictu

A new missense mutation in exon 6 of the
โœ Chiaki Kawanishi; Hitoshi Osaka; Kenji Owa; Ken Inoue; Tomohiro Miyakawa; Hideki ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB ๐Ÿ‘ 2 views

Duchenne muscular dystrophy (DMD) is an X-linked degenerative disorder of muscle, caused by gross rearrangements by the dystrophin gene in two-thirds of cases. The remaining one-third of patients may carry more subtle mutations that are difficult to detect because of the large size and complexity of